Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336936 | 0.89 | FGFR3 (0.76) | FGFR3KDR | |
| SCHEMBL3320087 | 0.88 | FGFR3 (0.79) | FGFR3KDR | |
| SCHEMBL3324620 | 0.87 | FGFR3 (0.78) | FGFR3KDR | |
| SCHEMBL3320526 | 0.87 | FGFR3 (0.80) | FGFR3KDR | |
| Formic Acid SCHEMBL3318919 | 0.87 | FGFR3 (0.73) | FGFR3KDR | |
| SCHEMBL3321564 | 0.86 | FGFR3 (0.77) | FGFR3KDR | |
| SCHEMBL3323574 | 0.86 | FGFR3 (0.78) | FGFR3KDR | |
| SCHEMBL13062801 | 0.86 | FGFR3 (0.82) | FGFR3KDR | |
| SCHEMBL13336792 | 0.86 | FGFR3 (0.88) | FGFR3KDR | |
| SCHEMBL13337003 | 0.85 | FGFR3 (0.77) | FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885KDR 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.